Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 10/20 | 0.70 |
| ▸ | PDE4D | Q08499 | 10/20 | 0.70 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.70 |
| ▸ | PDE4A | P27815 | 9/20 | 0.67 |
| ▸ | PDE4C | Q08493 | 9/20 | 0.67 |
| ▸ | PDE5A | O76074 | 1/20 | 0.62 |
| ▸ | PDE1A | P54750 | 1/20 | 0.62 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.62 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7176867 | 0.97 | PDE4B (0.66) | PDE4BPDE4DMAPK14PDE4APDE4C | |
| SCHEMBL7384113 | 0.94 | PDE4B (0.62) | PDE4BPDE4DMAPK14PDE4APDE4C | |
| SCHEMBL14003536 | 0.94 | PDE4B (0.61) | PDE4BPDE4DMAPK14PDE4APDE4C | |
| SCHEMBL27472680 | 0.89 | PDE4D (0.68) | PDE4BPDE4DMAPK14PDE4APDE4C | |
| SCHEMBL8885266 | 0.89 | PDE4B (0.81) | PDE4BPDE4DMAPK14PDE4APDE4C | |
| SCHEMBL30009845 | 0.88 | PDE4B (0.80) | PDE4BPDE4DMAPK14PDE4APDE4C | |
| SCHEMBL4728938 | 0.88 | PDE4B (0.80) | PDE4BPDE4DMAPK14PDE4APDE4C | |
| SCHEMBL1028427 | 0.88 | PDE4B (0.80) | PDE4BPDE4DMAPK14PDE4APDE4C | |
| SCHEMBL71331 | 0.87 | PDE4D (0.65) | PDE4BPDE4DMAPK14PDE4APDE4C | |
| SCHEMBL5309884 | 0.87 | PDE4D (0.67) | PDE4BPDE4DMAPK14PDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1289557-B1 | CANCER TREATMENT COMPOSITION CONTAINING AN ANTI-NEOPLASTIC AGENT AND A PDE4 INHIBITOR | GLAXO GROUP LTD (GB) | 2006-07-12 | — | — | EP | claimed |
| US-5124455-A | Enzyme inhibitors | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-06-23 | — | — | US | claimed |
| EP-0470805-A1 | Oxime-carbamates and oxime-carbonates as bronchodilators and anti-inflammatory agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-02-12 | — | — | EP | claimed |
| US-8450319-B2 | Pyrrolopyridazinone compound | UBE INDUSTRIES, LTD. (JP) | 2013-05-28 | — | — | US | disclosed |
| EP-1982986-B1 | PYRROLOPYRIDAZINONE COMPOUND AS PDE4 INHIBITOR | UBE INDUSTRIES (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20110112079-A1 | PHOSPHODIESTERASE INHIBITORS | THE GOV. OF THE U.S.A. AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH AND HUMAN SERVICES | 2011-05-12 | — | — | US | disclosed |
| US-20100324091-A1 | Pyrazolone Derivative | KOWA COMPANY, LTD. (JP) | 2010-12-23 | — | — | US | disclosed |
| EP-2231669-A1 | PHOSPHODIESTERASE INHIBITORS | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) | 2010-09-29 | — | — | EP | disclosed |
| EP-2172458-A1 | PYRAZOLONE DERIVATIVE | Kowa Company, Ltd. (JP) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009089027-A1 | PHOSPHODIESTERASE INHIBITORS | GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICE, NATIONAL INSTITUTES OF HEALTH (US) | 2009-07-16 | — | — | WO | disclosed |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | UBE INDUSTRIES, LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-0640065-A1 | TRISUBSTITUTED PHENYL DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS AND PROCESSES FOR THEIR PREPARATION | CELLTECH THERAPEUTICS LIMITED (GB) | 1995-03-01 | — | — | EP | disclosed |
| US-5393788-A | Phenylalkyl oxamides | SMITHKLINE BEECHAM CORPORATION (US) | 1995-02-28 | — | — | US | disclosed |
| WO-1994020446-A1 | TRISUBSTITUTED PHENYL DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS AND PROCESSES FOR THEIR PREPARATION | CELLTECH THERAPEUTICS LIMITED (GB) | 1994-09-15 | — | — | WO | disclosed |
| EP-0470805-B1 | Oxime-carbamates and oxime-carbonates as bronchodilators and anti-inflammatory agents | AMERICAN HOME PROD (US) | 1994-09-07 | — | — | EP | disclosed |
| EP-0550576-A1 | PHENYLPYRIDINOL DERIVATIVES AS MEDICAMENTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1993-07-14 | — | — | EP | disclosed |
| US-5124455-A | Enzyme inhibitors | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-06-23 | — | — | US | disclosed |
| WO-1992006085-A1 | PHENYLPYRIDINOL DERIVATIVES AS MEDICAMENTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1992-04-16 | — | — | WO | disclosed |
| CN-1058771-A | Method for making of oxime carbamate and oxime carbonate ester and uses thereof | AMERICAN HOME PROD (US) | 1992-02-19 | — | — | CN | disclosed |
| EP-0470805-A1 | Oxime-carbamates and oxime-carbonates as bronchodilators and anti-inflammatory agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-02-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112079-A1 | PHOSPHODIESTERASE INHIBITORS | PDE5A, PDE3B, PDE3A | PDE4B 7/4885PDE4D 9/4885MAPK14 3165/4885 |
| US-20100324091-A1 | Pyrazolone Derivative | SERPINE1, SERPINC1, TFPI | PDE4B 1700/4885PDE4D 1519/4885MAPK14 1326/4885 |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | CBR3, CBR1, CYC1 | PDE4B 3261/4885PDE4D 3827/4885MAPK14 2900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.